CareDx: Shaking Off First-Mover Disadvantage (NASDAQ:CDNA)
seekingalpha.com
economics
2022-10-18 16:41:15

CatLane/E+ via Getty Images Investment Thesis The healthcare industry has made significant strides in treating and diagnosing disease, but a considerable gap exists in identifying complications before they manifest. With proper patient monitoring, early interven­tion can be achieved, reducing the need for expensive treatments. Organ transplant rejection is one area where monitoring and early intervention can make a huge difference for patients, payors, and providers. CareDx (NASDAQ:CDNA) a molecular diagnostics company, has developed a non-invasive organ transplant ­scoring system that predicts the risk of organ rejection within a window of three days to three months after transplant surgery.
